SCHEMBL3967754

SCHEMBL3967754

O=Cc1ccc(C2CC(c3ccccn3)=NO2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
METAP1 P53582 2/20 0.38
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PTPN1 P18031 4/20 0.35
S1PR1 P21453 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
FAAH O00519 5/20 0.34
LMNA P02545 2/20 0.34
PRKCZ Q05513 1/20 0.34
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
BLM P54132 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12922862 0.84 PTPN1 (0.46) CA12CA9METAP1KDM4EPTPN1
SCHEMBL3969735 0.82 CA12 (0.39) CA12CA9METAP1KDM4EPTPN1
SCHEMBL12922851 0.82 PTPN1 (0.41) CA12CA9METAP1KDM4EALDH1A1
SCHEMBL3967752 0.82 CA12 (0.39) CA12CA9METAP1KDM4EPTPN1
SCHEMBL3972723 0.81 CA12 (0.40) CA12CA9METAP1KDM4EPTPN1
SCHEMBL3970160 0.81 MEN1 (0.49) PTPN1S1PR1MEN1KMT2ATSHR
SCHEMBL3975065 0.79 S1PR1 (0.53) KDM4EALDH1A1SMN1; SMN2PTPN1S1PR1
SCHEMBL12922849 0.77 S1PR1 (0.47) CA12CA9METAP1KDM4EALDH1A1
SCHEMBL3969051 0.77 MAOB (0.42) PTPN1S1PR1MEN1KMT2A
SCHEMBL12922858 0.76 CYP2A6 (0.44) CA12CA9SMN1; SMN2PTPN1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 CA12 439/4885CA9 122/4885METAP1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.